XML 29 R18.htm IDEA: XBRL DOCUMENT v3.25.3
GOODWILL AND INTANGIBLE ASSETS
 6 Months Ended
Sep. 27, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS
11. GOODWILL AND INTANGIBLE ASSETS
The changes in the carrying amount of goodwill by operating segment for fiscal 2026 are as follows:
PlasmaBlood CenterHospitalTotal
(Dollars in Thousands)
Carrying amount as of March 29, 2025
$29,043 $26,967 $548,259 $604,269 
Currency translation— 123 1,709 1,832 
Carrying amount as of September 27, 2025
$29,043 $27,090 $549,968 $606,101 
The gross carrying amount of intangible assets and the related accumulated amortization as of September 27, 2025 and March 29, 2025 are as follows:
Gross Carrying
Amount		Accumulated
Amortization		Net Carrying AmountWeighted Average Remaining Life (Years)
September 27, 2025
(Dollars in Thousands)
Amortizable:
Developed technology$509,111 $174,864 $334,247 12.1
Customer contracts and related relationships137,366 74,105 63,261 12.6
Capitalized software94,135 79,435 14,700 6.7
Patents and other7,468 4,348 3,120 10.0
Trade names16,082 6,841 9,241 12.3
Total$764,162 $339,593 $424,569 
Non-amortizable:
In-process software development$3,788 
Total$3,788 
Gross Carrying
Amount		Accumulated
Amortization		Net Carrying AmountWeighted Average Remaining Life (Years)
March 29, 2025
(Dollars in Thousands)
Amortizable:
Developed technology$506,143 $156,123 $350,020 12.1
Customer contracts and related relationships135,561 70,842 64,719 12.6
Capitalized software85,528 76,185 9,343 6.9
Patents and other19,678 6,796 12,882 8.5
Trade names15,955 6,367 9,588 12.3
Total$762,865 $316,313 $446,552 
Non-amortizable:
In-process software development$9,190 
Total$9,190 
In the second quarter of fiscal 2026, the Company recorded an intangible asset impairment charge of $8.6 million related to the intellectual property associated with the HAS viscoelastic diagnostic devices, related assays and disposables within the Hospital business unit, as acquired from HemoAssay Science and Technology (Suzhou) Co. Ltd., a China-incorporated company, and its affiliates (collectively, “HemoAssay”) in fiscal 2021. The impairment charge was the result of lower revenue projections of the HemoAssay devices and disposables. The fair value as September 27, 2025 was $1.6 million with a useful life of 5 years. We calculated the fair value of the HemoAssay intangible assets as the present value of estimated future cash flows we expect to generate from the assets based on estimates and assumptions about future revenues, costs and the remaining useful lives of the assets.
During the second quarter of fiscal 2026, we performed an impairment analysis for certain other amortizable intangible assets based on undiscounted cash flows and concluded those assets were not impaired. We will continue to review intangible assets subject to amortization for impairment indicators in future periods in accordance with our normal review processes.
Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names.
During the three and six months ended September 27, 2025, amortization expense was $12.8 million and $26.1 million, respectively. During the three and six months ended September 28, 2024, amortization expense was $14.2 million and $28.7 million, respectively.
Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:
Amortization Expense
(Dollars in Thousands)
Remainder of Fiscal 2026$24,914 
Fiscal 2027$48,158 
Fiscal 2028$46,382 
Fiscal 2029$45,135 
Fiscal 2030$43,873